Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/21/2016 |
| Start Date: | March 2002 |
| End Date: | February 2013 |
Multicenter Phase II Trial of OSI-774 (Erlotinib, Tarceva) In Patients With Advanced Bronchioloalveolar Cell Lung Cancer
The purpose of this study is:
- To measure the ability of OSI-774 to effectively treat bronchioloalveolar cell lung
cancer.
- To see whether the use of OSI-774 provides meaningful symptomatic benefit in patients
with advanced bronchioloalveolar cell lung cancer.
This study is a Phase II study. The first study of OSI-774 was done to evaluate what dose
should be given to patients with cancer has been completed. The purpose of this research
study is to see whether this experimental treatment, called OSI-774, can cause a type of
non-small cell lung cancer to stop growing or shrink. This study is sponsored by a company
called Genentech, and is being done at Memorial Hospital, as well as other cancer centers
around the country interested in developing new drugs for the treatment of this type of
cancer.
- To measure the ability of OSI-774 to effectively treat bronchioloalveolar cell lung
cancer.
- To see whether the use of OSI-774 provides meaningful symptomatic benefit in patients
with advanced bronchioloalveolar cell lung cancer.
This study is a Phase II study. The first study of OSI-774 was done to evaluate what dose
should be given to patients with cancer has been completed. The purpose of this research
study is to see whether this experimental treatment, called OSI-774, can cause a type of
non-small cell lung cancer to stop growing or shrink. This study is sponsored by a company
called Genentech, and is being done at Memorial Hospital, as well as other cancer centers
around the country interested in developing new drugs for the treatment of this type of
cancer.
Inclusion Criteria:
- Either bronchioloalveolar cell carcinoma or a variant thereof after review
- Clinical stage IIIB (malignant pleural or pericardial effusion) or IV or
recurrent/medically inoperable disease
- Measurable or evaluable indicator lesions
- No prior or one chemotherapy regimen for NSCLC
- Three weeks since last chemotherapy, and three weeks since prior radiation therapy to
a major bone-marrow containing area
- Karnofsky performance status > or = to 80% OR ECOG performance status ≤ or = to 1
- Life expectancy > or = to 8 weeks
- Adequate hematologic, renal and/or hepatic function: WBC > or = to 3,000/ul,
hemoglobin > or = to 9.0 g/dl, platelet count > or = to 100,000/ul, total bilirubin <
or = to 1.0 mg/dl, AST < than or = to 2.5 X UNL, creatinine < or = to 1.5 mg/dl or
Clcr > or = to 55ml/min.
- Effective contraception
Exclusion Criteria:
- Prior exposure to OSI-774 or other treatments targeting the HER family axis
(e.g.-trastuzumab, ZD1839, C225, etc.)
- Two or more prior chemotherapy regimens
- Concurrent active cancer
- Uncontrolled central nervous system metastases (i.e. any known CNS lesion which is
radiographically unstable, symptomatic and/or requiring escalating doses of
corticosteroids)
- Pregnant or lactating women
- Malignancies within the past 5 years except for adequately treated carcinoma of the
cervix or basal or squamous cell carcinomas of the skin
- Prior systemic cytotoxic chemotherapy for other malignant disease
- Significant medical history or unstable medical condition (unstable systemic disease:
congestive heart failure, recent MI, unstable angina, active infection, uncontrolled
hypertension).
We found this trial at
1
site
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
